Cytek Biosciences Inc — Liquidità Trimestrale (NASDAQ:CTKB) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 499.5 M482.6 M493.32 M494.92 M461.54 M Totale passività 103.76 M102.97 M115.76 M116.35 M119.8 M Patrimonio netto totale 395.74 M379.62 M377.56 M378.57 M341.74 M Totale passività e patrimonio netto 499.5 M482.6 M493.32 M494.92 M461.54 M Debito totale 12.36 M11.9 M18.23 M17.24 M17.45 M Indebitamento netto -86.36 M-83.39 M-57.23 M-76.04 M-73.41 M

Notizie

Cytek Biosciences alla TD Cowen Health Care: Approfondimenti sulla Crescita Strategica

Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences earnings missed by $0.32, revenue topped estimates

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:CTKB) 2026-01-15

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth (CTKB)

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Beyond Meat (NASDAQ:BYND), Avadel Pharmaceuticals (NASDAQ:AVDL)

Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates

Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?